目的 分析冠心病伴抑郁与胃癌伴抑郁的靶点、核心药物与作用机制，探讨二者“异病同治”的科学内涵。方法 检索自建库至2023年7月19日收录于中国知网（CNKI）、万方（Wanfang）、维普（VIP）、中国生物医学文献（CBM）数据库的冠心病伴抑郁与胃癌伴抑郁相关文献，筛选并构建数据库，对纳入处方中药进行频数统计、关联规则分析以及核心药物预测。结合GEO、Genecards、OMIM、TTD、DisGeNet数据库获取冠心病、胃癌、抑郁交集靶点，HERB数据库获取核心药物靶点，得到核心药物与疾病交集靶点。运用CytoHubba插件筛选核心基因，应用DAVID数据库进行基因本体论（gene ontology，GO）和京都基因与基因组百科全书（Kyoto encyclopedia of genes and genomes，KEGG）通路富集分析。结果 研究共纳入文献109篇，其中冠心病伴抑郁处方79首，胃癌伴抑郁处方30首。核心药物组合为“柴胡-甘草-白芍-当归”，并初步筛选出其“同治”冠心病伴抑郁与胃癌伴抑郁的核心靶点为白细胞介素-6（interleukin-6，IL-6）、肿瘤坏死因子（tumor necrosis factor，TNF）、缺氧诱导因子1α（hypoxia inducible factor-1α，HIF1A）、基质金属蛋白酶9（matrix metalloproteinase 9，MMP9）、肿瘤蛋白P53（tumor protein 53，TP53）等。共同富集通路主要有癌症通路、脂质和动脉粥样硬化、糖尿病并发症中的晚期糖基化终产物-晚期糖基化终产物受体（advanced glycation end products-receptor for advanced glycosylation end products，AGE-RAGE）信号通路、缺氧反应因子-1（hypoxia-inducible factor-1，HIF-1）信号通路等。结论 中医药治疗冠心病伴抑郁与胃癌伴抑郁符合“异病同治”理论，遵循中医共性病因病机要素与“虚、瘀、毒、郁”有关，病变脏腑为心、肝、脾、胃，治疗予以扶正基础上的化瘀解毒开郁大法，为临床重大慢性疾病防治提供一定参考。

Objective To analyze the targets, core drugs and mechanisms of coronary heart disease (CHD) with depression and gastric cancer (GC) with depression, and to explore the connotation of “treating different diseases with same method”. Methods The literatures related to CHD with depression and GC with depression collected from CNKI, Wanfang, VIP and CBM were retrieved from the self-built database until July 19, 2023, and the database was screened and constructed. The frequency statistics, association rule analysis and core drug prediction were carried out. Combining GEO, Genecards, OMIM, TTD, and DisGeNet databases to obtain CHD, GC, and depression intersection targets. The core drug target was obtained based on HERB database, and the core drug-disease intersection targets were obtained. Core genes were screened using CytoHubba plug-in, gene ontology (GO) and Kyoto encyclopedia of Genes and genomes (KEGG) pathway enrichment analysis were conducted using DAVID database. Results A total of 109 literatures were included, including 79 CHD with depression prescription and 30 GC with depression prescription. The core drug combination was “Chaihu (Bupleuri Radix)-Gancao (Glycyrrhizae Radix et Rhizoma)-Baishao (Paeoniae Radix Alba)-Danggui (Angelicae Sinensis Radix)”, and the core targets of CHD with depression and GC with depression were interleukin-6 (IL-6), tumor necrosis factor (TNF), hypoxia inducible factor-1α (HIF1A), matrix metalloproteinase 9 (MMP9), tumor protein 53 (TP53), etc. The co-enrichment pathways mainly include lipid and atherosclerosis, cancer pathway, advanced glycation end products-receptor for advanced glycosylation end products (AGE-RAGE) signaling pathway in diabetic complications, hypoxia-inducible factor-1 (HIF-1) signaling pathway, etc. Conclusion In the treatment of CHD with depression and GC with depression in line with the “treating different diseases with same method”, the common etiological factors of TCM are related to “deficiency, stasis, toxicity and depression”. The diseased organs are the heart, liver, spleen and stomach. The treatment should be based on the method of reinforcing healthy qi, removing blood stasis and toxin, and relieving depression, which can provide a reference for the prevention and treatment of major chronic diseases in clinics.

Q811.4;R285;TP18

国家自然科学基金项目（82174246）；国家重点研发计划（2019YFC1708701）